All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

AACR 2017 | Poster 3651/24 – Preclinical examination of the effects of a CD20-specific engineered toxin body, MT-3724, in Mantle Cell Lymphoma

By Terri Penfold

Share:

Apr 10, 2017


At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Tuesday 4th April, a poster session titled “BITES Bispecifics and Checkpoints” took place.

One of the posters on display (3651 / 24) was titled “Preclinical examination of the effects of MT-3724, an engineered toxin body targeting CD20, in mantle cell lymphoma” by Shengjiang Huang from the University of Texas MD Anderson Cancer Center, Houston, TX, and colleagues.

MT-3724 binds CD20 and is take up by the cell where the toxin travels to the cytosol to enzymatically and permanently inactivates ribosomes preventing protein synthesis. MT-3724 may decrease cell proliferation and induce apoptosis in MCL.

The group analyzed the effects of MT-3724 by in vitro cell proliferation in 3 ibrutinib-sensitive cell lines and 5 ibrutinib-resistant cell lines (4 primary resistant and 1 acquired resistant). Levels of apoptotic cells in ibrutinib-sensitive and -resistant cell lines treated with MT-3724 was measured by Annexin V/ PI staining. In addition, an in vivo efficacy assay of MT-3724 in a MCL PDX model, derived from a patient resistant to a wide-range of drugs including ibrutinib, was conducted.

Key Highlights:

  • MT-3724 effectively and efficiently inhibited cell proliferation in a dose-dependent manner in the majority of ibrutinib-sensitive and -resistant cell lines
  • IC50 <500ng/ml was considered as sensitive to MT-3724 and IC50 >500ng/ml was determined resistant to MT-3724
  • Three ibrutinib-sensitive cell lines (Jeko-1, Mino, and Rec-1) were sensitive to MT-3724: IC50 values = 139.1, 309.3, and 457.7ng/ml, respectively
  • Four ibrutinib-resistant cell lines (Maver-1, JVM-13, Jeko-R, and Granta519) were sensitive to MT-3724: IC50 values = 124.6, 155.1, 266.2, and 442.4ng/ml, respectively
  • One cell line (Z-138) was resistant to MT-3724 (IC50 = 1231ng/ml)
  • No significant differences in IC50 values found between ibrutinib-sensitive and -resistant cell lines (P = 0.36)
  • In a time-dependent assay, 300ng/ml MT-3724 decreased cell proliferation in two ibrutinib-sensitive cell lines (Mino and Jeko-1) and two resistant cell lines (Jeko-R and Maver-1)
  • MT-3724 induced apoptosis in both sensitive (Jeko-1) and resistant (Jeko-R and Maver-1) lines
  • Apoptosis was induced by MT-3724 by increasing expression of cleaved PARP, as well as decreasing expression of BCL-2 and MCL-1
  • MT-3724 was administered via intraperitoneal injection for three consecutive weeks in PDX model resistant to a wide-range of targeted agents; MT-3724 greatly reduced tumor burden and increased survival (median of 27 days) of the PDX mice

In conclusion, MT-3724 appears to be a potential therapeutic agent for combating ibrutinib resistance in MCL; combinations with this agent should be investigated to achieve higher efficacy.

References

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?